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ABSTRACT
Background & Aims: There is high need of novel diagnostic and prognostic tools 
for tumors of the digestive system, such as gastric cancer and cholangiocarcinoma. We 
recently found that miR-204 was deeply downregulated in gastric cancer tissues. Here 
we investigated whether this was common to other tumors of the digestive system 
and whether this elicited a miR-204-dependent gene target signature, diagnostically 
and therapeutically relevant. Finally, we assessed the contribution of the identified 
target genes to the cell cycle progression and clonogenicity of gastric cancer and 
cholangiocarcinoma cell lines. 
Methods: We employed quantitative PCR and Affymetrix profiling for gene 
expression studies. In silico analysis aided us to identifying a miR-204 target 
signature in publicly available databases (TGCA). We employed transient transfection 
experiments, clonogenic assays and cell cycle profiling to evaluate the biological 
consequences of miR-204 perturbation. 
Results: We identified a novel miR-204 gene target signature perturbed in gastric 
cancer and in cholangiocarcinoma specimens. We validated its prognostic relevance 
and mechanistically addressed its biological relevance in GC and CC cell lines. 
Conclusions: We suggest that restoring the physiological levels of miR-204 in 
some gastrointestinal cancers might be exploited therapeutically.
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding 
RNAs that control gene expression through base pairing 
with specific sequences in the 3’-UTR of target mRNAs. 
For their ability to modulate simultaneously the levels of 
multiple gene products, microRNAs are invaluable tools 
at integrating intracellular signaling with changes in the 
extracellular and intracellular milieu, thus conferring 
spatial and temporal modulation to cell signaling [1]. 
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MicroRNAs may play a role in cancer progression 
functioning as oncogenes or tumor suppressors [2-5]. In 
line with this, it is not surprising that specific miRNA 
signatures have been associated with specific stages of 
tumor progression, including response to chemotherapy. 
Consequently, microRNA signatures may be endowed 
with prognostic and diagnostic potential. 
Gastric cancer (GC) is the fifth most frequently 
diagnosed cancer and the third leading cause of death 
related to cancer worldwide [6]. The two main histo-types 
of gastric cancer are the intestinal and the diffuse one [7, 
8]. 
The hepato-biliary tumors are a heterogeneous 
group of poor prognosis cancers localized to the liver, gall 
bladder and biliary tree [9]. Establishing the true incidence 
of bile duct cancer is very difficult because, to date, there 
are no specific and sensitive diagnostic tools. Based on the 
location of the tumor cholangocarcinoma can be classified 
in intrahepatic or extrahepatic cholangiocarcinoma [9, 10].
MicroRNAs, as being exquisite transducers of 
micro-environmental signaling and sensitive sensors of the 
tissue homeostasis, can be ideal tools to finely pinpoint 
the molecular status of a tissue. In facts microRNAs 
are emerging as effective biomarkers for the differential 
diagnosis of the tumors, as being proven to discriminate 
tumoral and normal tissues of various cancer type such as, 
breast cancers, mesothelioma, head and neck squamous 
carcinoma and osteosarcomas [11-14].
In a previous study we profiled microRNA 
differentially expressed in gastric cancer vs matched 
normal tissue specimens and miR-204 was among those 
differentially modulated in a cohort of 123 matched tissues 
[14]. MiR-204 was also reported as down regulated in 
several cancers, including biliary-tree tumors [14-17]. 
However, little is known about the miR-204 gene targets 
in various tumors and, more, whether perturbation of miR-
204-dependent gene signatures may contribute to tumor 
progression. 
Taking the start from our previous observations, we 
here evaluated the expression of the miR-204 in a series 
of tumors of the digestive system and we mechanistically 
dissected its contribution to tumor progression. Our study 
hypothesis was that the deep downregulation of the miR-
204 in tumor tissues may underlie a very relevant event in 
the progression of the disease, possibly by triggering gene 
expression changes, impinging on key protumorigenic 
properties of the transformed cells. As such, miR-204 
levels may be diagnostically and prognostically relevant. 
We first aimed at deeply characterize the expression 
of miR-204 in a sizable cohort of gastric cancer specimens 
(as compared to normal tissues) to identify, by combining 
transcription profiling and extensive in silico analysis, 
the potential targets of this microRNA. This allowed 
us to identify 37 gene targets with prognostic potential 
for gastric cancer in Kaplan Meier analysis. Next, we 
observed that miR-204 down regulation was a rather 
general feature of other tumors of the digestive system, 
also including colon, esophageal cancer and hepatocellular 
carcinoma, which all exhibited a similar degree of miR-
204 perturbation. We focused on a rare type of digestive 
system cancer, the cholangiocarcinoma, because of the 
availability of a unique large repertoire of specimens in 
our network. We found that the miR-204 levels, deeply 
downregulated in cholangiocarcinomas as opposed to 
normal tissues, correlated with a gene signature almost 
identical to that observed in gastric cancer specimens. 
Among the identified gene targets (common to both gastric 
cancer and cholangiocarcinomas) we identified a 7-gene 
signature, which exhibited, collectively, prognostic value 
in Kaplan Meier analysis. We showed that manipulating 
the levels of miR-204 (by means of agonist molecules) 
in representative GC and CC cell lines, led to a reversal 
of the identified gene target signature. This affected the 
clonogenicity and cell cycle progression of the transfected 
cell lines, thus establishing a mechanistic link between the 
modulation of miR-204 targets and the protumorigenic 
properties of the tumor cells. Finally, we evaluated by 
siRNA-mediated silencing, the biological activity of 
each one of the targets toward cell cycle progression and 
clonogenicity of gastric tumor and cholangiocarcinoma 
cells.
RESULTS
We recently identified microRNAs differentially 
modulated in a limited set of matched samples of tumor 
and normal tissues from gastric carcinoma patients 
[14]. The microRNA-204 (miR-204) was among the 
differentially modulated microRNAs and a component of 
a prognostically relevant signature [14]. To deepen those 
previous findings, we specifically evaluated the expression 
of microRNA-204 in a novel discovery set of 20 frozen 
gastric specimens (15 tumor and 5 normal gastric mucosa) 
(Table 1), by quantitative PCR (Figure 1A). This showed 
that the miR-204 levels were much lower in tumor tissues 
as compared to normal tissues, in line with our previous 
observations (Figure 1A) [14]. To statistically strengthen 
this finding, we employed a larger cohort of 276 Tumor 
and 38 Normal samples from publicly available gene 
expression databases (TCGA), as a validation set (Table 1) 
(Figure 1B). Again, we observed similar modulation of the 
miR-204 in the validation set (Figure 1B). Of note, we also 
found that a deeper downregulation of the miR-204 levels 
was a feature of the “intestinal” histotype as opposed to 
the “diffuse” histotype of gastric cancer (Supplementary 
Figure 1A). The Intestinal-type gastric cancer is by far 
the most common variant of gastric cancer (accounting 
for 50-70% of the cases) (WHO classification of tumours 
of the digestive system. Lyon: International Agency for 
Research on Cancer; 2010). Next, we set out to better 
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understand the contribution of miR-204 downregulation 
to the progression of GC. As microRNAs work mainly 
by targeting the expression of multiple mRNAs through 
base paired interactions within their 3’-UTR region, we 
set out to determine the targets of miR-204 in the tumor 
tissues analyzed. To do this, we aimed at identifying 
mRNAs whose expression anti-correlated with that of the 
microRNA-204 and which contained a microRNA-204 
seed sequence in their 3’-UTR region by means of an 
Affymetrix-based profiling in our discovery set as assessed 
in Figure 1A (Table 1) (Figure 1C). Extensive in silico 
analysis (Supplementary Figure 1B) allowed us to identify 
37 gene targets, which obeyed to the mentioned criteria 
(Table 3). Indeed, such gene targets, belonging to distinct 
biological processes (Table 4A-4B), exhibited increased 
expression in tumoral vs normal samples in both our 
discovery set (Figure 1C, heat map) and in the validation 
set from TGCA database examined (Figure 1D, heat 
map). Principal component analysis (PCA) performed 
on the gene expression levels of the 37 genes in both 
our discovery set and in the TGCA samples revealed 
that the expression levels of the microRNA-204 targets 
could effectively discriminate between tumor and normal 
samples (Figure 1E, left panel) and between tumor and 
normal tissue (Figure 1F, right panel), respectively. This 
was true for both the “intestinal” and “diffuse” histotype 
of gastric cancer (data not shown). We further refined our 
analysis and we focused on seven out of 37 identified 
targets (NOTCH1, FOXM1, RAD51, CENP-A, CENP-E, 
KIF15, SHCBP1), which showed a significantly high 
Table 1: List of gastric cancer specimens analyzed and clinical information.
DISCOVERY SET VALIDATION SET (TGCA)
FROZEN 
TISSUES
KM PLOTTER 
SET
N N N N
NUMBER OF PATIENTS 20* 220 40 876
SEX    
M 9 140 20 545
F 7 80 20 236
HISTOLOGICAL TYPE    
Diffuse 8 57 10 241
Intestinal 7 140 24 320
Hepatoid 1  2
Mixed  16  
Not available  7 4 
TUMOR SIZE (T)    
T0 1
T1 1 9 2 14
T2 2 33 7 241
T3 8 126 16 204
T4 5 52 10 38
Not available
NODAL STATUS (N)    
N0 2  18 74
N+ 14  18 422
Not available  4
GRADING (G)    
G1 0 26 0
G2 2 99 17
G3 10 84 14
G4 2 11 1
Unknown 2   8
Discovery set used for the Affymetrix profiling is composed of 20 samples of which 15 tumoral and 1 un-matched normal 
gastric mucosa and 4 normal matched gastric mucosae.The validation set is composed of unmatched samples from the TGCA 
database. Clinical information were available for 220 out of the 314 analyzed patients.Frozen matched samples were used 
for qPCR validation. KM plotter dataset used for KM analysis. The clinical information available are reported in the table.
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Figure 1: miR 204 and its target gene signature can discriminate between normal and tumoral gastric tissues. A.-B. 
Boxplots. Expression level of miR-204 in a discovery set of tumor (n = 15) and normal (n = 5) gastric tissues. Normalized expression levels 
as assessed by Quantitative PCR. B. Expression levels of miR204 in a validation set of 264 tumoral and 38 normal gastric sample tissues 
from the TGCA database. C.-D. Heatmap. Unsupervised hierarchical clustering of the levels of 37 genes targets anti-correlated with miR-
204 expression and which contained a miR-204 seed sequence in 3’UTR region (see Table 1) in both the discovery set C. and in the TGCA 
dataset. Normalized intensity values reported. D. E-F. Principal Component Analysis (PCA) of the distribution of the 37 genes (as from 
1C-1D) in the discovery set E. and in the TGCA dataset F. The first component (PC1) represents inter-group variability (x-axis) while the 
second component (PC2) represents the intra-group variability (y-axis).
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Pearson anti-Correlation value in the cohorts analyzed 
and belonged to similar biological processes (Table 3 and 
Table 4).
We choose to further study the expression of 
CENP-A, SHCBP-1, FOXM1, KIF15, in a cohort of 
40 matched frozen tissue specimens (Table 1) (Figure 
2A), previously characterized for the miR-204 levels 
(Supplementary Figure 2A). We observed that the 
expression of two out these four genes targets (FOXM1 
and KIF15) significantly and positively correlated with 
the node (N) status of the patient (Supplementary Figure 
2B). Next, we evaluated whether the higher levels of 
the representative genes examined would correlate with 
patient survival, by Kaplan-Meier analysis (KMplotter.
com). This showed that the identified genes contributed 
prognostic potential, with higher expression of the gene 
correlating with decreased patient survival. This was true 
when analyzing both the 37 and the 7 genes signature 
(Figure 2B left and right panel, respectively).
We also identified a subset of 20 of the 37 genes 
(including 15 genes common to TGCA and KM plotter 
datasets) significantly associated to the overall survival of 
the patients when the latter were stratified according to the 
tumor histotype, by univariate analysis (Figure 2C left and 
right panel, Supplementary Table 1). This correlated with 
a deeper downregulation of miR-204 in the “intestinal” 
histotype (Supplementary Figure 1A), and with higher 
levels of its representative candidate targets (Table 5 and 
Supplementary Figure 5, respectively).
MiR-204 is downregulated in GI tumors
In order to assess whether the miR-204 
downregulation and its consequent alteration of gene 
transcription would be a gastric cancer specific lesion, we 
analyzed the levels of expression of miR-204 in matched 
tissues from other tumors of the digestive system, by 
Table 2: List of cholangiocarcinoma specimens analyzed and clinical information.
FROZEN 
TISSUES  FFPE TISSUES TGCA
N N N
NUMBER OF PATIENTS 26 19 36
SEX    
M 17 10 16
F 9 9 20
HISTOLOGICAL TYPE    
intra-hepatic 13 10 30
extra-hepatic 13 8 6
TUMOR SIZE (T)    
T1 2 1 19
T2 12 15 12
T3 7 1 5
T4 1  0
Unknown 3 (biopsy) 2  
NODAL STATUS (N)    
N0 11 10  
N+ 12 6  
Unknown 3 (biopsy) 1  
GRADING (G)    
G1 1  19
G2 12 5 9
G3 10 9 1
G4 0  7
Unknown 3 (biopsy) 2  
Frozen matched tissues were characterized for miR 204 and targets genes expression level. FFPE samples were used for 
studying the miR 204 expression analysis comparing cholangiocarinoma with matched un-affected biliary tract tissues. TGCA 
database was used to enforce our results.
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Figure 2: Tumor-expressed miR-204 targets may have prognostic potential. A. Box plots. Expression levels of CENP-A, 
SHCBP1, FOXM1, KIF15, in tumor vs normal tissue samples as evaluated by quantitative RT-PCR of 41 fresh matched tissues, previously 
characterized for the miR-204 levels (Supplementary Figure 2A). B. Kaplan-Meier analysis. Higher levels of the 37 whole gene signature 
(left panel) and of the selected 7 gens (FOXM1, RAD51, KIF15, CENP-A, CENP-E, NOTCH1, SHCBP1) (right panel) correlated with 
decreased patient survival. C. Kaplan-Meier analysis. tA subgroup of mir-204 gene targets predicted overall survival of GC patients 
carrying the intestinal GC histotype. Overall survival calculated on patients bearing intestinal (left panel) or diffuse (right panel) GC 
histotype, according to the gene set shown in Supplementary Table 1. 
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employing the TCGA database. This revealed that the 
miR-204 was downregulated in 103 colon tumor tissues 
as compared to normal colon mucosa (Supplementary 
Figure 4A); we also observed that the microRNA-204 was 
deeply downregulated in 12 esophageal cancer tissues vs 
its normal counterpart (Supplementary Figure 4B) and, 
Table 3: Putative miR-204 gene targets selected according to the criteria described in the text.
GENE/miR204 GC GENE/miR204 TGCA GC GENE\miR204 TCGA CCA
GENE n° prediction tool R Pearson p value R Pearson p value R Pearson p value
RCC2 4 -0,9259432 4,8531E-09 -0,39189627 2,0096E-11 -0,37019042 0,01231233
STIL 4 -0,90967035 2,72938E-08 -0,44694006 1,14003E-14 -0,38264482 0,00948156
MKI67 4 -0,90660095 3,64488E-08 -0,36256828 6,35967E-10 -0,50656626 0,00038426
ARHGAP11A 5 -0,89475864 1,02086E-07 -0,40569912 3,49858E-12 -0,42570867 0,00355126
RAD51 5 -0,89072633 1,41036E-07 -0,31617519 7,6835E-08 -0,43233349 0,00301837
CDCA8 4 -0,88927317 1,57974E-07 -0,28193562 1,62836E-06 -0,49308009 0,00057882
SHCBP1 5 -0,88424802 2,31111E-07 -0,24936578 2,08907E-05 -0,47218798 0,00105717
KIF15 5 -0,88160634 2,80337E-07 -0,38587499 4,20188E-11 -0,42592368 0,00353275
FOXM1 4 -0,86068505 1,11981E-06 -0,28869853 9,18839E-07 -0,52210414 0,00023458
CENPE 5 -0,86029691 1,1465E-06 -0,36510107 4,78314E-10 -0,45798201 0,00155894
CENPA 5 -0,85914302 1,22917E-06 -0,29483137 5,39816E-07 -0,50666915 0,00038304
NOTCH1 6 -0,84324211 3,02813E-06 -0,28549794 1,20686E-06 -0,21394612 0,15818325
RACGAP1 4 -0,84295458 3,07508E-06 -0,3469437 3,49224E-09 -0,50154541 0,00044846
CCNF 5 -0,83267343 5,22975E-06 -0,30009111 3,38701E-07 -0,4391877 0,00254234
PDGFRB 5 -0,82538503 7,46221E-06 -0,21481712 0,000219939 -0,14263023 0,34996411
CDC25B 6 -0,81115812 1,42879E-05 -0,28939643 8,65415E-07 -0,39632472 0,00703537
SLC27A2 6 -0,80642962 1,75228E-05 -0,28327399 1,45574E-06 0,167963321 0,27007769
EPHB2 6 -0,8036086 1,97406E-05 -0,28920466 8,79792E-07 -0,26614462 0,07720508
FLVCR2 5 -0,80297101 2,02742E-05 -0,0582144 0,17304948 0,135952614 0,37320902
PAICS 4 -0,79451311 2,8629E-05 -0,32532083 3,17611E-08 0,038792834 0,80026628
MSR1 5 -0,78443992 4,23269E-05 -0,28314372 1,47174E-06 -0,02154619 0,88827667
PLXNA1 4 -0,78286517 4,49122E-05 -0,31782911 6,56325E-08 -0,32716505 0,02825738
CDH13 4 -0,78204978 4,63035E-05 -0,28911799 8,86364E-07 -0,26173396 0,08242663
CLDN1 5 -0,77870607 5,24052E-05 -0,34912016 2,76994E-09 -0,23370431 0,12232108
HSPH1 7 -0,770814 6,96208E-05 -0,26576022 6,02835E-06 -0,04712768 0,75852626
SCD 5 -0,76457661 8,64784E-05 -0,15310422 0,006377357 0,194194475 0,20116229
RTKN2 7 -0,76044893 9,94697E-05 -0,20430407 0,000420274 -0,3266414 0,0285259
LOXL2 5 -0,75798142 0,00010801 -0,19661312 0,000661776 -0,38198982 0,00961508
CACYBP 5 -0,75630081 0,000114181 -0,39534122 1,30887E-11 -0,39391464 0,00742171
MMP3 5 -0,75226712 0,000130239 -0,16531766 0,003552365 NA NA 
KIAA1199 4 -0,74112207 0,000185051 -0,17897512 0,001762564 -0,23281225 0,12379495
F2R 5 -0,73972529 0,000193143 -0,19232703 0,000846249 -0,07661501 0,61691822
INHBA 7 -0,73433465 0,000227276 -0,27265961 3,48467E-06 -0,18796101 0,21628935
MANEAL 4 -0,7321102 0,000242795 -0,23681267 5,11871E-05 0,036703909 0,81081924
PKM2 4 -0,72843075 0,000270451 -0,21819256 0,000177462 -0,45360692 0,00175125
TFAP2A 4 -0,71306986 0,000416889 -0,24246373 3,43952E-05 -0,48946511 0,00064417
FAP 7 -0,71170461 0,000432668 -0,20515966 0,000399165 -0,2879022 0,0551385
 For each gene are reported the number of the microRNA target prediction tools used for the analysis, and the Pearson anti-
Correlation value and the p-value  calculated for our discovery set, for the gastric TGCA dataset, and the cholangiocarcinoma 
TGCA dataset, respectively.
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Figure 3: MiR-204 and its target gene signature are differentially expressed in cholangiocarcinoma tissues. A.-C. 
Expression levels of miR-204 in a discovery set of 26 freshly frozen A. and 19 FPPE B. cholangiocarcinoma samples as compared to 
matched normal biliary duct tissues (for the extra-hepatic cholangiocarcinoma) or to hepatic, non tumoral tissues (for the intra-hepatic 
cholangiocarcinoma), as assessed by quantitative RT-PCR. C. Expression levels of miR-204 in a validation set obtained from the TGCA 
database (n = 45). D. Expression levels of representative miR-204 target genes as assessed by quantitative PCR from freshly frozen tumor 
vs normal tissues (n = 26). CENP-E is not significant upregulated.
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finally, albeit with less statistical strength, we found 
reduced miR-204 expression in 49 hepatic carcinoma 
tissues (Supplementary Figure 4C). 
Hepatic cholangiocarcinomas exhibited deep miR-
204 downregulation and high levels of its target 
gene signature
We evaluated the levels of miR-204 in 26 frozen 
cholangiocarcinoma tissues and in 19 FFPE samples as 
opposed to matched normal biliary duct tissues (Table 
2). This revealed that the miR-204 was lower in the 
tumor as opposed to matched normal tissues (Figure 
3A). This happened irrespectively whether the RNA 
was derived from FFPE material or from frozen tissues 
(Figure 3A-3B). Analysis of the miR-204 expression 
in 45 cholangiocarcinoma specimens from the TCGA 
database (Table 2) confirmed our observation (Figure 
3C). Next, we assessed the levels of the seven miR-204 
gene targets (those already characterized in the gastric 
cancer specimens). Again, consistently with the prior 
observation, quantitative PCR of 26 frozen matched 
cholangiocarcinoma specimens revealed that the 7 genes 
selected exhibited significantly higher levels in the tumor 
tissues as opposed to the normal ones (Figure 3D). The 
analysis of samples in our cohort also showed that the 
degree of downregulation of the miR-204 and of some 
of its targets (SHCBP1, CENPA, RAD51) was higher in 
the intrahepatic cholangiocarcinoma samples as opposed 
to the extrahepatic ones (Supplementary Figure 5A). We 
extended the analysis of the levels of the whole set of 
the previously identified miR-204 targets on the 45 CC 
samples from TGCA database. This revealed that the 
selected 36 out 37 targets (expression data for MMP3 was 
not available) were differentially modulated among tumor 
and normal tissues derived from the cholangiocarcinoma 
patients (Figure 4A), again consistently to what observed 
in the gastric cancer specimens (Table 3). PCA analysis 
showed that the identified 36-target gene signature could 
effectively discriminate between tumor and normal tissue 
(Figure 4B). This was clearly illustrated, for gastric 
cancer and cholangiocarcinoma, by the Volcano plots in 
Figure 4C-4D (Figure 4C-4D, respectively) and was true 
also for esophageal cancer in Supplementary Figure 6 
(Supplementary Figure 6). This revealed a high degree 
of similarity about the modulation of miR-204 and the 
perturbation of its target genes among three unrelated 
tumors of the digestive system.
Restoring miR-204 level in GC and CC cell lines 
impinged on the expression of common gene 
targets
In order to investigate a causal relationship between 
the lower levels of the miR-204 and the higher levels of 
its anti-correlated targets, we manipulated the levels of 
Table 4: A. Gene Ontology of the 37 miR-204 target genes. B. Gene Ontology of the 7 miR-204 target genes.
A
GO terms p-value NUMBER OF GENES
positive regulation of cellular process 1.92E-5 19
cellular component organization or biogenesis 8.07E-5 19
positive regulation of biological process 9.61E-5 19
developmental process 7.86E-4 18
single-organism developmental process 7.29E-4 17
organelle organization 8.45E-5 13
positive regulation of macromolecule metabolic process 1.49E-4 13
cell cycle process 2.46E-6 11
regulation of cell proliferation 2.11E-4 10
B
GO terms p-value GENES
nuclear division 8,60E+11 cenpa, kif15, cenpe, rad51
mitotic cell cycle process 2,92E-03 cenpa, foxm1, kif15, cenpe
positive regulation of macromolecule metabolic process 7,35E-02 notch1, foxm1, cenpe, rad51
protein-DNA complex assembly 3,05E-03 cenpa, cenpe, rad51
mitotic nuclear division 9,94E-03 cenpa, kif15, cenpe
cellular macromolecular complex assembly 4,86E-02 cenpa, cenpe, rad51
protein complex assembly 9,51E-02 cenpa, cenpe, rad51
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Figure 4: The miR-204 target gene signature is enriched in cholangiocarcinoma tissues A. Heatmap. Unsupervised 
hierarchical clustering of the expression levels of 36 putative miR-204 gene targets (see table 1 please). B. Principal Component Analysis 
(PCA) of the distribution of the 36 genes in the TGCA dataset. C. Volcano plots. Analysis of the distribution of the miR-204 levels and 
those of its putative target genes revealed similar relationship in both gastric cancer and cholangiocarcinoma samples. The log
2
 fold change 
is plotted on the x-axis and the negative log10 of the p-value is plotted on the y-axis.
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the miR-204 in two representative GC and CC cell lines 
(GTL-16 and HUCCT1, respectively). We transfected both 
cell lines with a control (ctrl) or a mimic-204 molecule 
(mimic-204) and transfection of the latter led to a dose 
dependent increase of the intracellular levels of the miR-
204 (Supplementary Figure 7A). Next, we assessed, by 
quantitative PCR, the levels of the seven target genes 
(CENP-A, SHCBP-1, FOXM1, KIF15, CENP-E, RAD51, 
NOTCH1) at 24hr, 48hr and 72hr from the transfection 
(10nM). Overexpression of the miR-204 agonist led to 
time-dependent, decreased expression of the levels of all 
7 representative gene targets (Figure 5A, left and right 
panels). Despite we observed a different kinetics in the 
GTL-16 as opposed to the HUCCT1 cells transfected 
with the mimic-204 molecule, in both cases we witnessed 
effective downregulation of the gene targets, compatible 
with a reversal of the miR-204 dependent gene expression 
(Figure 6A, left and right panels, respectively) (p < 0.05 at 
72hrs). Notably, the effect of transfecting the mimic-204 
into both cell lines was conserved even when much lower 
doses of the agonist were employed, 4nM and 2,5nM 
respectively (supplementary Figure 7B-7C) as opposed 
to10nM-shown in Figure 5A. On the other hand, when we 
transfected GTL-16 and HUCCT1 cells, stably expressing 
miR-204 with a miR-204 antagomiR molecule (and a 
control molecule), we witnessed upregulation of 6 out of 
the 7 miR-204 targets (Supplementary Figure 8). Next, 
we evaluated the cell cycle profile of the CTRL- and 
mimic-204- transfected cells. FACS staining of both GTL-
16 and HUCCT1 cells, stained with propidium iodide, 
revealed a time dependent effect of the agonist treatment 
on the cell cycle, consisting of an increased G1/S phase, 
which was maximal at 72hrs (Figure 5B upper and lower 
panels). We also evaluated, by western blotting of whole 
cell lysates from GTL-16 and HUCCT1 cells treated with 
the mimic-204, the expression of the p21 protein, known 
to increase in cells in G1/S. Compatible with the flow 
cytometry data, we observed a sharp increase of the p21 
protein in the mimic-204 treated cells, as compared to 
their control counterparts (Figure 5C, left and right panel). 
Altering the miR-204 levels affects clonogenicity
Next, we assessed whether manipulating the levels 
of the miR-204 gene targets in the GTL-16 and HUCCT1 
cells, by means of transfecting mimic-204, could affect 
some of their protumorigenic properties. To this aim we 
performed clonogenic assays. This strategy revealed 
that the clonogenicity of the both cell lines was affected 
upon overexpression of the miR-204 mimic molecule 
as compared to the control-transfected cells (Figure 
5D). These results are compatible with the previously 
mentioned involvement of most of the miR-204 candidate 
targets in the cell cycle control. 
Table 5:  OZ-ratio and p-value of each miR-204 target 
gene with regard to the tumor histotype (intestinal vs 
diffuse). 
GENE HISTOTYPE
 OZ-ratio p value
CENPA 3,524655 8,88E-10
CDCA8 3,218823 7,91E-09
KIF15 3,872278 9,54E-09
STIL 3,194886 1,17E-08
RACGAP1 3,569596 2,64E-08
CENPE 3,054833 3,76E-08
SHCBP1 3,390914 4,79E-08
FOXM1 2,801849 4,82E-08
CCNF 3,165557 5E-08
RAD51 2,871915 1,79E-07
ARHGAP11A 2,652069 2,42E-07
PAICS 4,033762 4,17E-07
SCD 1,910822 9,21E-07
MKI67 2,289854 1,04E-06
PDGFRB 0,376828 1,32E-06
CACYBP 4,86563 1,75E-06
RCC2 4,101644 2,01E-06
CDC25B 2,151685 3,19E-05
SLC27A2 1,636207 6,22E-05
MANEAL 1,725689 6,34E-05
F2R 0,540483 0,00118
MMP3 1,280282 0,002059
RTKN2 2,634362 0,002575
FAP 0,644902 0,002973
MSR1 0,63902 0,004153
HSPH1 1,736864 0,004854
TFAP2A 1,377954 0,012011
PKM2 1,704638 0,015133
KIAA1199 1,215815 0,03566
FLVCR2 1,526833 0,038384
EPHB2 1,212687 0,055602
CDH13 0,841145 0,298352
NOTCH1 0,835771 0,308333
INHBA 0,88429 0,309716
LOXL2 1,157181 0,388079
PLXNA1 1,174817 0,517301
CLDN1 0,947998 0,601849
In bold the significant ones are indicated.
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Figure 5: Restoring miR-204 levels in gastric and cholangiocarcinoma cancer cells affects the target signature and 
some protumorigenic properties of the GTL-16 and HUCCT1 cells. A. Heat map depicting the expression levels of the indicated 
miR-204 targets in the GTL-16 and HUCCT1 cell lines transfected with 10 nM of control (ctrl) or mimic-204 and harvested at 24hr, 48hr 
and 72hr. Normalized expression levels determined by quantitative PCR. The target gene/GAPDH ratio is reported as folds over control. 
B. mimic-204 treatment affects cell cycle. Upper panel. Representative histograms showing the DNA content of GTL-16 (left panel) and 
HUCCT-1 cells (right panel) stained with propidium iodide at 72 hours after transfection with a control- or the miR-204 agonist. Lower 
panel. Representative histograms showing the cell cycle distribution of GTL-16 (left panel) and HUCCT-1 cells (right panel) treated as 
from upper panel. Histogram bars represent the mean ± SE of duplicate experiments. Asterisks: *p < 0,05; **p < 0,01; ***p < 0,001. 
C. Western blotting with p21 antibody of whole cell lysates of GTL-16 (upper panel) and HUCCT1 (lower panel) cells harvested at 
72hrs after transfection with a control or a mimic-204. Tubulin staining was used as a loading control. D. Clonogenic assays. Left panel. 
Representative micrographs of colonies formed by the GTL-16 and HUCCT1 cells transfected with a control (ctrl) or a miR-204 agonist 
molecule (mimic-204) for 96hrs before seeding at clonal density. Histograms bars represent the mean ± SE of triplicate experiments in 
GTL-16 and HUCCT1 cell lines. Statistics p < 0,05 except where indicated.
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Interference of single miR-204 target genes affects 
cell cycle and clonogenicity
It is known that the biological effects of the 
expression of a given microRNA, are mediated by the 
modulation of clusters of target genes rather than single 
targets. However, to detail the mechanism of action of 
the mimic-204, we aimed to investigate which of the 
miR-204 target gene(s) could mostly influence the miR-
204 phenotype. Therefore we transfected the HUCCT1 
and the GTL-16 cells with siRNAs targeting each gene 
of the 7-target signature (Supplementary Figure 9) and 
we evaluated the effect of the silencing by means of 
FACS analysis (cell cycle) and clonogenic assays (Figure 
6). Staining of the cells with propidium iodide at 72h 
following siRNA transfection revealed that downregulation 
of each miR-204 target affected to a varying degree the 
Figure 6: Downregulation of the single miR-204 targets recapitulates the biological effects of miR-204 expression. 
Representative histograms showing the DNA content of HUCCT-1 A. and GTL-16 B. cells stained with propidium iodide at 72 hrs after 
transfection with siRNA of the indicated targets. C.-D. clonogenic assay Representative micrographs of colonies formed by HUCCT1 C. 
and GTL-16 D. cells transfected with the indicated siRNA for 72hrs before seeding at clonal density. Histograms bars represent the mean 
± SE of triplicate experiments in GTL-16 and HUCCT1 cell lines. Effective silencing was assessed by qPCR (mRNA) data not shown. 
Statistics p < 0,05 except where indicated. 
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cell cycle of the transfected cells, compatible with the 
different biological activities of each of the targets. In 
detail, silencing of SHCBP1 in HUCCT1 cells strongly 
increased the Sub-G1 cells (Figure 6A). Similar effects 
were also consequent to silencing of CENP-E and FOXM1 
and for NOTCH1, RAD51 and CENP-A (Figure 6A-6B). 
Silencing of the mentioned genes affected very similarly 
both the GTL-16 and HUCCT1 cells, with the exception 
of FOXM1 in the GTL-16 cells (Figure 6B). Clonogenic 
assays revealed that silencing of each of the target caused 
a reduction in colony formation, thus fully matching 
what observed when ectopically expressing the miR-204 
(Figure 6C-6D). Interestingly, silencing of KIF15 did not 
affect and rather increased the colony forming ability of 
both the transfected cell lines, despite silencing of the 
latter elicited increased sub-G1 cells in both cell lines 
(Figure 6C-6D). Altogether, these observations suggested 
that increasing the miR-204 intracellular levels triggered 
effects on the cell cycle and clonogenic ability of the cells 
which could be partially recapitulated by silencing each of 
the single miR-204 targets,
DISCUSSION
In this experimental work we have detailed the 
modulation of microRNA-204 in both gastric carcinoma 
and cholangiocarcinoma samples, which exhibited 
common downregulation of this microRNA in the tumor 
tissues as opposed to normal tissues. We have identified, 
in silico, a 37-gene target signature whose levels anti-
correlated with those of the miR-204 and shown that 
20 out of 37 genes exhibited prognostic potential in 
GC, with some of the genes of the signature exhibiting 
independent prognostic potential, in Kaplan-Meier 
analysis. We have also shown that altering the miR-204 
levels in both gastric carcinoma and cholangiocarcinoma 
cells changed the levels of the miRNA-204 targets genes 
in a direction compatible with a reversal of the miR-204-
dependent effect. Last but not least, exogenously added 
miR-204 affected the cell cycle progression and inhibited 
the clonogenicity of the transfected cells. The miR-204 
is a well-characterized microRNA, already shown to be 
downregulated in many solid tumors [15, 18, 19]. Despite 
the fact that its mode of action and its effector targets may 
differ according to the tissue of origin and the stage of the 
tumor, there is indication that it may represent a general 
tumor suppressor [15, 18-24]. Thus, the data collected 
here for both GC and CC specimens and the experiments 
performed in the GTL-16 and HUCCT1 cells are in 
line with the literature data. This is significant since the 
collections of specimens analyzed highly differed for their 
source (FFPE vs frozen) and time of collection (TCGA vs 
home-made casuistries) and came from different centers. 
All these factors could strongly influence the interpatient 
heterogeneity and contribute significant biases to the 
analysis.
Notably, 36 out of the identified 37 genes 
were identically modulated in gastric cancer, 
cholangiocarcinoma and esophageal cancers tissues as 
well, thus highlighting the potential relevance of the low 
levels of the miR-204 observed in GI tumors types. In 
facts, it is not very common that unrelated tumors exhibit 
a high degree of similarity in their gene expression profile 
and this may further suggest a relevant effect of the miR-
204 downregulation on the progression of the diseases.
The primary sclerosing cholangitis (PSC) is 
a chronic liver disease characterized by cholestasis, 
inflammation and fibrosis and it is known to progress to 
cholangiocarcinoma (CC) [25, 26]. Recently, a distinct 
set of microRNAs was identified from sera of patients 
affected by PSC and CC [27]. Notably, no upregulated 
miR-204 was observed by Bernuzzi et al. both in the 
PSC and the CC patient sera. However, it remains to be 
addressed whether reduced expression of miR-204 would 
be observed in PSC tissues rather than in patient sera and 
whether expression of miR-204 may represent a biomarker 
of progression to CC. 
On this line, we found here that the intestinal type 
of gastric tumors in the TGCA cohorts exhibited a deeper 
miR-204 downregulation and, consequently, higher 
levels of its gene target signature. Although the limited 
data available here do not allow deriving conclusions, it 
would be tempting in the future to investigate whether our 
observation may possess patient stratification potential. 
Here we partially addressed the specific contribution 
of each miR-204 gene target to the cell cycle progression 
and clonogenicity of the GTL-16 and HUCCT1 cells. We 
found that SHCBP1, RAD51, CENP-A, CENP-E and 
NOTCH1 were mainly responsible for the “mimic-204 
phenotype”. More in detail, while silencing of SHCBP1, 
RAD51, NOTCH1 and FOXM1 significantly increased 
the cells in the sub-G1 phase, all of the tested miR-204 
targets (except for KIF15) affected the clonogenicity of 
the transfected cell lines. Downregulation of NOTCH1, 
among the targets, resulted in effective increase of 
sub-G1 cells, in line with the NOTCH signaling being 
a major player in cholangiocarcinoma progression with 
translational potential for cholangiocarcinoma [28-31]. 
On the other hand, we did not observe significant 
induction of sub-G1 cells when transfecting the mimic-204 
in both GTL-16 and HUCCT1 cells. Thus, targeting of the 
single targets did not fully mimic the effect of miR-204 
expression. This apparent discrepancy may be explained 
by the observation that, with regard to the action of the 
microRNA, it is the coordinated increase of the levels of 
all or some of its targets that impinges significantly on 
the overall phenotype. Additionally, in vitro experiments 
revealed that the seven representative target genes 
exhibited different kinetics of modulation in time. This 
may be accounted by differences in the steady-state levels 
of the target mRNAs, different accessibility of the 3’-
UTR, or cell subpopulation-specific expression of some 
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targets, within the cell lines examined. With regard to this, 
we also observed different kinetics between the two cell 
lines analyzed (GTL-16 and HUCCT1, respectively, with 
the GTL-16 exhibiting a earlier modulation of the targets 
when transfected with the mimic-204 (as compared with 
the HUCCT1 cells, transfected in very similar conditions). 
This would be, possibly, due to different proliferation 
rates or intracellular processing of the mimic molecules 
between the GC and the CC cells.
Last but not least, all of the samples included in our 
casuistries (both gastric cancer and cholangiocarcinoma) 
derived from patients not previously treated with 
chemotherapy. This is an important point. In fact, our and 
others published work indicate that miR-204 may play 
a role in determining chemoresistance, at least partially 
through the modulation of the anti-apoptotic BCL2 
protein, in gastric [14] and breast cancer cells [32]. We 
aim to perform more studies to investigate how the levels 
of miR-204 are modulated in chemotherapy-treated gastric 
cancer and cholangiocarcinoma cell lines and, importantly, 
whether the chemotherapy-induced stress may change the 
spatial and/or temporal modulation of its targets.
MATERIALS AND METHODS
Study population
In the present study 40 gastric surgical specimens 
from patients who underwent resection for cancer at 
the Regina Elena Cancer Institute and 11 specimens 
from the Sant’ Andrea Hospital, Rome, were included 
MiR-204 levels were also analyzed from 26 fresh 
cholangiocarcinoma tissues of patients who underwent 
resection for tumor at Regina Elena Cancer Institute 
and from 19 cholangiocarcinoma formalin embedded 
tissues (FFPE) from the Sant’ Orsola Hospital, Bologna. 
Case series included also additional hepatic fresh frozen 
tissues samples, corresponding to 23 HCC and to 11 
liver metastases, from Regina Elena Cancer Institute. For 
each patient, we collected tissue samples from the tumor 
lesion and from the uninvolved mucosa, defined as the 
portion of tissue located at 2 cm from the safe resection 
margin of the tumor lesion. Data regarding patients’ 
demographics, clinical and pathological features as well 
as the clinical outcomes were obtained from prospectively 
collected databases. The ethical committees of each of the 
mentioned institutes have approved the study.
RNA extraction
Fresh frozen tissues samples were obtained 
immediately after surgical resection and stored in RNA 
later (THERMOFISHER, MA USA) to stabilize and 
protect RNA in fresh specimens. After disruption and 
homogenization in QIAzol Lysis Reagent (QIAGEN, 
Chatsworth, CA) RNA was extracted using miRNeasy Kit 
(QIAGEN Chatsworth, CA) following the manufacturer’s 
instructions. The concentration, purity and quality control 
of RNA extracted were assessed using Agilent 2100 
Bioanalyzer. RNA from FFPE samples was extracted 
using the miRneasy® FFPE kit (QIAGEN Chatsworth, 
CA) following the manufacturer’s instructions. Total RNA 
from cell lines was extracted using the TRIZOL Reagents 
(GIBCO).
Gene expression profiling
15 tumoral and 5 normal gastric tissues from Regina 
Elena Cancer Institute and Sant’ Andrea Hospital were 
analyzed for mRNA expression using GeneChip® Human 
Gene 1.0 ST Array and processed by the Affymetrix 
Expression Console and normalization.
cDNA synthesis and qRT-PCR
One microgram of total RNA was reverse-transcribed 
at 37°C for 60 minute in the presence of random hexamers 
and Moloney murine leukemia virus reverse transcriptase 
(Invitrogen). Specific oligonucleotide primers for 
GAPDH, CENP-A, CENP-E, RAD 51, FOXM1, 
SHCBP1, KIF15, and NOTCH 1 were used for PCR 
analyses. GAPDH: FW GAGTCAACGGATTTGGTCGT_
RV GACAAGCTTCCCGTTCTCAG; CENP-A: 
FW GGCCCTATTGGCCCTACAAG_RV 
GAGTAACTCGGCCTGCATGT; CENP-E: 
FW GAGGTGCAAAATGCAGGAGC_RV 
CACATCCTTGCCTGAGGAGG; KIF15: 
FW AAGCTCCACAAGGAATCCCG_RV 
ACTCTGGGGTGGTGCTCTAT; SHCBP1: 
FW CCTGCTTCGAAGGTGACACT_RV 
TATCAGCACCAGTGCAGTCC; RAD51: 
FW TGCGACTCGCTGATGAGAGTTT_RV 
AAACATCGCTGCTCCATCCA; FOXM1: 
FW TGCAGCTAGGGATGTGAATCTTC_RV 
GGAGCCCAGTCCATCAGAACT; NOTCH1: 
FW AGCATCACCTGCCTGTTAGG_ RV 
TGGCATACACACTCCGAGAA. Gene expression levels 
were measured by quantitative real-time PCR using the 
SYBR Green assay (Applied Biosystems, Carlsbad, CA, 
USA) on a StepOne instrument (Applied Biosystems).
Small amounts of RNA (10 ng) were reverse 
transcribed using the TaqMan microRNA Reverse 
Transcription Kit (Applied Biosystems) in a final volume 
of 10ul using a ABI Prism 7000 Sequence Detection 
System (Applied Biosystems). The PCR Reactions were 
initiated with a 10 minute incubation at 95°C followed 
by 40 cycles of 95°C for 15 seconds and 60°C for 60 
seconds. Q-PCR quantification of miRNA expression was 
performed using TaqMan MicroRNA® Assays (Applied 
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Biosystems) according to the manufacturer’s protocol. 
RNU6B was used as endogenous control to normalize 
miRNA expression. All reactions were performed in 
duplicate.
Cell cultures and treatments
Human gastric cancer cell lineGTL-16 was 
grown in DMEM medium (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS), penicillin (100 
U/ml) and streptomycin (100ug/ml) at 37°C in a 
balanced air humidified incubator with 5% CO2. The 
cholangiocarcinoma cell line HUCCT1 was grown in 
RPMI medium (Invitrogen) supplemented with 10% 
fetal bovine serum (FBS), penicillin (100 U/ml) and 
streptomycin (100ug/ml) at 37°C in a balanced air 
humidified incubator with 5% CO2.
Plasmids and transfections
All miRNA mimics, inhibitors, and non-targeting 
negative controls were purchased from THERMO 
FISHER (THERMO FISHER MA, USA) and were 
transfected using Lipofectamine RNAi MAX (Invitrogen) 
according to the manufacturer’s instructions. For mature 
miR-204-5p expression, we used Pre-miRNA Precursor-
Negative Control (THERMO FISHER, MA, USA) and 
Pre-miRNA204-5p (THERMO FISHER, MA, USA) 
at final concentration of 10nM, 4nM 2,5nM. For the 
Inhibition experiments GTL-16 and HUCCT1 stable 
expressing miR 204 were transfected with antagomiR of 
miR-204-5p and antagomiR-NC (THERMO FISHER, 
MA, USA) according to the manufacturer’s instructions. 
GTL-16 and HUCCT1 cells were transfected 
with siRNA of NOTCH1, RAD51, CENP-A, CENP-E, 
FOXM1, KIF15, SHCBP1 for 72 hrs using Lipofectamine 
RNAi MAX (Invitrogen) according to the manufacture’s 
instructions. siGFP was used as control. Effective 
silencing was assessed by qPCR (mRNA). 
Sequences of siRNA used: RAD51: 
UGUAGCAUAUGCUCGAGCG; 
CENPA:CACAGUCGGCGGAGACAAG ; 
CENP-E: AAGCAGAGAGAAGGGUGAACC; 
SHCBP1: GCUGAAACUCAUUGAGAAU; KIF15: 
GCAUGUACAGCUUCAAUUAUU; NOTCH1: 
AAGUGUCUGAGGCCAGCAAGA; FOXM1: 
AUAAUUAGAGGAUAAUUUG
Flow cytometry
Exponentially growing cells were collected at 
different time points after transfection. Cells were 
harvested, washed with PBS1x, resuspended in PBS1x/
EDTA 5mM, fixed in 70% ETOH/PBS1x and stored 
at - 20°C.Fixed cells were treated with RNase at final 
concentration of 1 mg/ml for 30 min at 37°C before 
addition of 5 mg/ml propidium iodide (PI) (Sigma) and 
analyzed with Guava Easy-cyte 8HT flow cytometer 
equipped with Guava Soft 2.1 (Millipore). For each 
measurement, at least 10,000 cells were acquired. 
Lysate preparation and immunoblotting analyses
Cells were lysed in buffer with 50 mM Tris-HCl 
pH.8, 150 mM NaCl, 5 mM EDTA, 1% NP-40 (Igepal 
AC-630). Extracts were centrifuged at 14000 rpm for 10 
min to remove cell debris. Protein concentrations were 
determined by colorimetric assay (Bio-Rad). Western 
blotting was performed using the following primary 
antibodies: mouse monoclonal anti-Tubulin (Abcam), 
rabbit monoclonal anti-p21 (cell signalling). Secondary 
antibodies used were goat anti-mouse, goat anti-rabbit 
conjugated to horseradish peroxidase (Amersham 
Biosciences, Piscataway, NJ, USA). Immunostained 
bands were detected by chemiluminescent method (Uvitec 
Alliance, Cambridge).
Colony-formation assay
1000 live GTL-16 or 500 HUCCT1 cells were 
transfected with Pre-miRNA Precursor-Negative Control 
(Ambion) and Pre-miRNA204 (Ambion) before seeding 
into 6-well dishes (COSTAR). Cells were stained with 
crystal violet and colonies counted after 7-10 days later.
Bionformatics and statistical analysis
Signals from gene expression profiling were 
background adjusted and quantile normalized. A 
permutation test and a false discovery procedure were used 
to identify most deregulated genes between tumoral and 
normal samples, setting to 0.05 the level of significance. 
Principal component analysis and unsupervised 
hierarchical clustering were performed on deregulated 
features. Several prediction target tools were interrogated 
by using the web server tool MirWalk2 (http://zmf.
umm.uni-heidelberg.de/apps/zmf/mirwalk2/) and the 
most predicted putative targets (at least four prediction 
software) of miR-204 selected to evaluate miRNA\mRNA 
correlation. A Pearson’s correlation coefficient and relative 
p-value were obtained for each miRNA-204\mRNA pairs, 
and genes with p-values less than 0.05 and absolute value 
coefficient higher than 0.7 were used for further analyses. 
The obtained signature was first validated in The Cancer 
Genome Atlas (TCGA) gastric adenocarcinoma and 
TCGA cholangiocarcinoma dataset, and only genes anti-
correlated to miR-204 were selected. A restricted list of 
genes were further validated by RT-PCR. All the analyses 
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were performed by Matlab (The MathWorks Inc.). For 
each box-plot shown outlier samples are indicated with 
asterisks. The survival analysis was performed using 
web server tool KM plotter. hght and low groups in KM 
Kaplan-Meier survival curves, was defined by median 
values of genes expression. Hazard ratio (HR), 95 % 
confidence intervals (CI), and log-rank p values are also 
indicated. Signal expression of the signature . aws defined 
by the mean intensity value.
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